CHL
MCID: HDG012
MIFTS: 77

Hodgkin Lymphoma (CHL) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Hodgkin Lymphoma

Aliases & Descriptions for Hodgkin Lymphoma:

Name: Hodgkin Lymphoma 54 12 50 24 13 14 38
Hodgkin Disease 12 50 66 52 41 69
Hodgkin's Lymphoma 38 12 50 14
Lymphoma, Hodgkin's 50 29
Hodgkin's Disease of Lymph Nodes of Inguinal Region and/or Lower Limb 69
Hodgkin's Disease of Intrapelvic Lymph Nodes 69
Stage Ii Subdiaphragmatic Hodgkin Lymphoma 12
Stage I Subdiaphragmatic Hodgkin Lymphoma 12
Lymphoma, Hodgkin, Classic 66
Classic Hodgkin Lymphoma 56
Classic Hodgkin Disease 56
Hodgkin's Sarcoma 12
Hodgkins Lymphoma 12
Chl 66
Hl 12

Characteristics:

Orphanet epidemiological data:

56
classic hodgkin lymphoma
Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-5/10000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: any age;

HPO:

32
hodgkin lymphoma:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Hodgkin Lymphoma

MedlinePlus : 41 hodgkin disease is a type of lymphoma. lymphoma is a cancer of a part of the immune system called the lymph system. the first sign of hodgkin disease is often an enlarged lymph node. the disease can spread to nearby lymph nodes. later it may spread to the lungs, liver, or bone marrow. the exact cause is unknown. hodgkin disease is rare. symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin fever and chills night sweats weight loss loss of appetite itchy skin to diagnose hodgkin disease, doctors use a physical exam and history, blood tests, and a biopsy. treatment depends on how far the disease has spread. it often includes radiation therapy or chemotherapy. the earlier the disease is diagnosed, the more effective the treatment. in most cases, hodgkin disease can be cured. nih: national cancer institute

MalaCards based summary : Hodgkin Lymphoma, also known as hodgkin disease, is related to hemophagocytic lymphohistiocytosis and ectodermal dysplasia, and has symptoms including ataxia, pruritus and fatigue. An important gene associated with Hodgkin Lymphoma is KLHDC8B (Kelch Domain Containing 8B), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Adcetris and Bexxar have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are immune system and hematopoietic system

Disease Ontology : 12 A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell.

OMIM : 54 Classic Hodgkin lymphoma is a lymph node cancer of germinal center B-cell origin. Hodgkin lymphoma tumors consist of a... (236000) more...

UniProtKB/Swiss-Prot : 66 Lymphoma, Hodgkin, classic: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed- Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.

Wikipedia : 71 Hodgkin\'s lymphoma (HL) is a type of lymphoma, which is generally believed to result from white blood... more...

Related Diseases for Hodgkin Lymphoma

Diseases related to Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 364)
id Related Disease Score Top Affiliating Genes
1 hemophagocytic lymphohistiocytosis 29.9 ALK CSF3 NPM1 PAX5 TNFRSF8
2 ectodermal dysplasia 29.2 ALK BCL2 BCL6 PAX5 PRDM1 REL
3 nodular lymphocyte predominant hodgkin lymphoma 12.2
4 lymphoma, non-hodgkin 12.2
5 classic hodgkin lymphoma, mixed cellularity type 12.0
6 classic hodgkin lymphoma, lymphocyte-rich type 12.0
7 non-hodgkin lymphoma, during pregnancy 12.0
8 hodgkin lymphoma, during pregnancy 12.0
9 lymphoma 12.0
10 non-hodgkin lymphoma, childhood 11.9
11 hodgkin lymphoma, childhood 11.9
12 gray zone lymphoma 11.8
13 hodgkin's lymphoma, nodular sclerosis 11.5
14 hodgkin's lymphoma, lymphocytic depletion 11.5
15 hodgkin's lymphoma, lymphocytic-histiocytic predominance 11.5
16 b-cell lymphomas 11.5
17 anaplastic large cell lymphoma 11.4
18 hodgkin's lymphoma, mixed cellularity 11.4
19 hepatic lipase deficiency 11.3
20 diffuse large b-cell lymphoma 11.3
21 follicular lymphoma 11.3
22 progressive transformation of germinal centers 11.3
23 paraneoplastic cerebellar degeneration 11.2
24 lymphoplasmacytic lymphoma 11.2
25 primary central nervous system lymphoma 11.2
26 plasmablastic lymphoma 11.2
27 composite lymphoma 11.2
28 mediastinal gray zone lymphoma 11.2
29 lymphoma, malt, somatic 11.2
30 familial hodgkin disease 11.0
31 follicular lymphoma 1 10.9
32 idiopathic cd4-positive t-lymphocytopenia 10.9
33 orbital lymphoma 10.9
34 granulomatous slack skin disease 10.9
35 primary oculocerebral lymphoma 10.9
36 hydrolethalus syndrome 10.8
37 lipase deficiency, combined 10.8
38 hmg-coa lyase deficiency 10.8
39 hodgkin's granuloma 10.5
40 primary mediastinal large b-cell lymphoma 10.5
41 rubella panencephalitis 10.3 BCL2 BCL6
42 leukemia 10.3
43 macrogyria, pseudobulbar palsy and mental retardation 10.3 ALK FAS NPM1
44 penile disease 10.3 ALK BCL6 TNFRSF8
45 nodular prostate 10.3 BCL2 BRAF IL6
46 ichthyosis, congenital, autosomal recessive 10 10.3 BCL2 BCL6
47 monostotic fibrous dysplasia 10.3 BRAF FSCN1 MS4A1
48 coloboma of iris 10.3 IL6 MS4A1
49 peripheral nervous system neoplasm 10.3 ALK CSF3 TNFRSF8
50 multiple mitochondrial dysfunctions syndrome 10.3 BCL6 IL6 PAX5

Graphical network of the top 20 diseases related to Hodgkin Lymphoma:



Diseases related to Hodgkin Lymphoma

Symptoms & Phenotypes for Hodgkin Lymphoma

Symptoms by clinical synopsis from OMIM:

236000

Clinical features from OMIM:

236000

Human phenotypes related to Hodgkin Lymphoma:

32 (show all 22)
id Description HPO Frequency HPO Source Accession
1 ataxia 32 HP:0001251
2 pruritus 32 HP:0000989
3 fatigue 32 HP:0012378
4 dyspnea 32 HP:0002094
5 fever 32 HP:0001945
6 headache 32 HP:0002315
7 hemoptysis 32 HP:0002105
8 chest pain 32 HP:0100749
9 bone pain 32 HP:0002653
10 hyperhidrosis 32 HP:0000975
11 splenomegaly 32 HP:0001744
12 hepatomegaly 32 HP:0002240
13 immunodeficiency 32 HP:0002721
14 weight loss 32 HP:0001824
15 peripheral neuropathy 32 HP:0009830
16 anorexia 32 HP:0002039
17 cough 32 HP:0012735
18 lymphoma 32 HP:0002665
19 lymphadenopathy 32 HP:0002716
20 polyclonal elevation of igm 32 HP:0003459
21 hodgkin lymphoma 32 HP:0012189
22 impaired lymphocyte transformation with phytohemagglutinin 32 HP:0003347

MGI Mouse Phenotypes related to Hodgkin Lymphoma:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.3 IL6 LTA LY75 MS4A1 NPM1 PAX5
2 hematopoietic system MP:0005397 10.28 BCL2 BCL6 BRAF CSF3 FAS IL6
3 cellular MP:0005384 10.22 FAS FSCN1 IL6 NPM1 PAX5 PRDM1
4 growth/size/body region MP:0005378 10.21 ALK BCL2 BCL6 BRAF FAS FSCN1
5 endocrine/exocrine gland MP:0005379 10.16 ALK BCL2 BCL6 BRAF FAS IL6
6 cardiovascular system MP:0005385 10.15 BRAF FAS IL6 LTA NPM1 PRDM1
7 mortality/aging MP:0010768 9.97 ALK BCL2 BCL6 BRAF FAS FSCN1
8 integument MP:0010771 9.92 ALK BCL2 BRAF CSF3 FAS IL6
9 liver/biliary system MP:0005370 9.86 PRDM1 REL BCL6 BRAF FAS IL6
10 neoplasm MP:0002006 9.56 FAS IL6 NPM1 PAX5 PRDM1 ALK
11 respiratory system MP:0005388 9.23 ALK BCL2 BCL6 BRAF FAS IL6

Drugs & Therapeutics for Hodgkin Lymphoma

FDA approved drugs:

(show all 10)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 46 BRENTUXIMAB VEDOTIN Seattle Genetics Approved August 2011
2
Bexxar 17 46 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa Approved June 2003
3
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Approved June 2006
4
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
5
Mozobil 17 46 PLERIXAFOR Genzyme Approved December 2008
6
Rituxan 17 46 RITUXIMAB Biogen IDEC, Genentech Approved November 1997
7
Sutent 17 46 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
8
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon Approved October 2008
9
Zevalin 17 46 IBRITUMOMAB TIUXETAN Biogen IDEC Approved February 2002
10
Zydelig 17 46 IDELALISIB Gilead Approved July 2014

Drugs for Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 574)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
4
Thiotepa Approved Phase 4,Phase 2,Phase 1 52-24-4 5453
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
8
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
9
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
10
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
11
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
12
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
13
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 174722-31-7 10201696
14
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
15
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Antilymphocyte Serum Phase 4,Phase 2,Phase 1
21 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
25 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
31 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
32 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
33 Hormones Phase 4,Phase 3,Phase 2,Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
35 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
36 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
37 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
40 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
41 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1
42 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
45 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
46 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
47
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
48
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
49
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
50
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 1191)
id Name Status NCT ID Phase
1 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4
2 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
4 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Recruiting NCT01088750 Phase 4
5 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4
6 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4
7 Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease Unknown status NCT00002987 Phase 3
8 Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3
9 Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma Unknown status NCT00025636 Phase 3
10 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
11 Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma Unknown status NCT00041210 Phase 3
12 Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma Unknown status NCT00678327 Phase 3
13 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
14 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
15 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
16 Exercise During Chemotherapy for Patients With Hematological Malignancies Unknown status NCT00884364 Phase 3
17 Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Completed NCT00038558 Phase 3
18 Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease Completed NCT00002561 Phase 3
19 Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) Completed NCT00443677 Phase 3
20 SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease Completed NCT00002495 Phase 3
21 Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease Completed NCT00003421 Phase 3
22 Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease Completed NCT00002827 Phase 3
23 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3
24 Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma Completed NCT01251107 Phase 3
25 Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease Completed NCT00005578 Phase 3
26 Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00070187 Phase 2, Phase 3
27 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed NCT01026220 Phase 3
28 A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) Completed NCT01034163 Phase 3
29 Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma Completed NCT00433433 Phase 3
30 Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Completed NCT00433459 Phase 3
31 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Completed NCT00039910 Phase 3
32 Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL Completed NCT01358747 Phase 3
33 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease Completed NCT00003414 Phase 3
34 HD11 for Intermediate Stages Completed NCT00264953 Phase 3
35 HD12 for Advanced Stages Completed NCT00265031 Phase 3
36 HD10 for Early Stages Completed NCT00265018 Phase 3
37 A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). Completed NCT00838357 Phase 3
38 Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy Completed NCT01085058 Phase 2, Phase 3
39 Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed NCT00928018 Phase 3
40 A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy Completed NCT00261677 Phase 3
41 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3
42 Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed NCT00398411 Phase 3
43 Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy Completed NCT00041665 Phase 3
44 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Completed NCT01188798 Phase 3
45 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
46 Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy Completed NCT00469729 Phase 2, Phase 3
47 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3
48 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3
49 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
50 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3

Search NIH Clinical Center for Hodgkin Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hodgkin Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Hodgkin Lymphoma

Genetic tests related to Hodgkin Lymphoma:

id Genetic test Affiliating Genes
1 Hodgkin Lymphoma 29 24 KLHDC8B

Anatomical Context for Hodgkin Lymphoma

MalaCards organs/tissues related to Hodgkin Lymphoma:

39
B Cells, Lymph Node, T Cells, Bone, Bone Marrow, Liver, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Hodgkin Lymphoma:
id Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Hodgkin Lymphoma

Articles related to Hodgkin Lymphoma:

(show top 50) (show all 1742)
id Title Authors Year
1
Correlation of Patterns of Bone Marrow Infiltration and Biochemical factors in Non-Hodgkin Lymphoma. ( 28523057 )
2017
2
Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States. ( 28065438 )
2017
3
Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy. ( 28498337 )
2017
4
Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. ( 28068241 )
2017
5
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. ( 28040700 )
2017
6
Mutation analysis of tumor necrosis factor alpha-induced protein 3 gene in Hodgkin lymphoma. ( 28189285 )
2017
7
Associations between genetic variants in immunoregulatory genes and risk of non-Hodgkin lymphoma in a Chinese population. ( 28060727 )
2017
8
Dietary inflammatory index and non-Hodgkin lymphoma risk in an Italian case-control study. ( 28503716 )
2017
9
Do polychlorinated biphenyls cause cancer? A systematic review and meta-analysis of epidemiological studies on risk of cutaneous melanoma and non-Hodgkin lymphoma. ( 28535466 )
2017
10
Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma. ( 28509575 )
2017
11
Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. ( 28504035 )
2017
12
Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis. ( 28531181 )
2017
13
Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma. ( 28515253 )
2017
14
Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. ( 28491264 )
2017
15
Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects. ( 28118119 )
2017
16
Targeting non-Hodgkin Lymphoma with Blinatumomab. ( 28532177 )
2017
17
Pure sensory ganglionopathy as the first sign of relapse in non-Hodgkin lymphoma. ( 28507261 )
2017
18
Acquired TEF in Hodgkin Lymphoma in a Child: A Rare Clinical Association. ( 28060119 )
2017
19
Cyclin D1 expression and polysomy in lymphocyte-predominant cells of nodular lymphocyte-predominant Hodgkin lymphoma. ( 28038705 )
2017
20
Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma. ( 28061782 )
2017
21
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
22
Synchronous Presentation of Renal Cell Carcinoma and Hodgkin Lymphoma in an Adolescent. ( 28092312 )
2017
23
Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation. ( 28092356 )
2017
24
Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. ( 28092347 )
2017
25
Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma. ( 28497317 )
2017
26
Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma. ( 28493609 )
2017
27
Small and big Hodgkin-Reed-Sternberg cells of Hodgkin lymphoma cell lines L-428 and L-1236 lack consistent differences in gene expression profiles and are capable to reconstitute each other. ( 28505189 )
2017
28
Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 28522441 )
2017
29
Periodontal disease and risk of non-Hodgkin lymphoma in the Health Professionals Follow-Up Study. ( 27861844 )
2017
30
Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. ( 28067872 )
2017
31
Late onset progressive multifocal leukoencephalopathy in Hodgkin lymphoma. ( 28526178 )
2017
32
An Unusual First Manifestation of Hodgkin Lymphoma: Epitrochlear Lymph Node A^nvolvement-A Case Report and Brief Review of Literature. ( 28508005 )
2017
33
Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. ( 27998726 )
2017
34
No association between radiation dose from pediatric CT scans and risk of subsequent Hodgkin lymphoma. ( 28052939 )
2017
35
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. ( 28512788 )
2017
36
Loss of Reelin suppresses cell survival and mobility in non-Hodgkin lymphoma. ( 28498462 )
2017
37
Characterization of Alstrom Syndrome 1 (ALMS1) Transcript Variants in Hodgkin Lymphoma Cells. ( 28135309 )
2017
38
Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. ( 28042455 )
2017
39
The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas. ( 26750138 )
2016
40
Methotrexate-Associated Classic Hodgkin Lymphoma in a Patient With Dermatomyositis. ( 27556248 )
2016
41
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). ( 27967294 )
2016
42
Blastomycosis infection in an adolescent patient with Hodgkin lymphoma. ( 27663466 )
2016
43
The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. ( 27431582 )
2016
44
An unusual clinical and pathological presentation of a nodular lymphocyte predominant Hodgkin lymphoma ("Poppema Lennert" lymphoma). ( 27532537 )
2016
45
PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas. ( 26549638 )
2016
46
Epstein-Barr virus latent membrane protein-1 upregulates cytokines and correlates with older age and poorer prognosis in Hodgkin lymphoma. ( 27632954 )
2016
47
Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 27999289 )
2016
48
The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma. ( 27598460 )
2016
49
Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas. ( 27282353 )
2016
50
Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience. ( 28083035 )
2016

Variations for Hodgkin Lymphoma

ClinVar genetic disease variations for Hodgkin Lymphoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 KLHDC8B NM_173546.2(KLHDC8B): c.-158C> T single nucleotide variant Pathogenic rs387906223 GRCh37 Chromosome 3, 49209095: 49209095

Cosmic variations for Hodgkin Lymphoma:

9 (show all 16)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 15
2 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 15
3 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 15
4 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 15
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 15
6 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 15
7 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 15
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 15
9 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 15
10 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 15
11 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 15
12 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 15
13 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 15
14 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 15
15 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 15
16 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 15

Copy number variations for Hodgkin Lymphoma from CNVD:

7 (show top 50) (show all 204)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 15434 1 115570986 115748025 Copy number Hodgkin''s lymphoma
2 18148 1 144224941 245407169 Copy number Hodgkin''s lymphoma
3 21362 1 158258490 227249364 Copy number Hodgkin''s lymphoma
4 29781 1 235850830 237390561 Copy number Hodgkin''s lymphoma
5 29922 1 238038528 245407169 Copy number Hodgkin''s lymphoma
6 35390 1 6293700 18251002 Copy number Hodgkin''s lymphoma
7 37216 1 87388008 120033702 Copy number Hodgkin''s lymphoma
8 37460 1 9146813 16679690 Copy number Hodgkin''s lymphoma
9 38491 10 102895110 124244273 Copy number Hodgkin''s lymphoma
10 40197 10 125057756 126954997 Copy number Hodgkin''s lymphoma
11 40637 10 131215760 132635356 Copy number Hodgkin''s lymphoma
12 41620 10 214400 133778456 Copy number Hodgkin''s lymphoma
13 41883 10 25240974 36004765 Copy number Hodgkin''s lymphoma
14 43571 10 46999355 135111152 Copy number Hodgkin''s lymphoma
15 43572 10 46999355 48101366 Copy number Hodgkin''s lymphoma
16 43573 10 46999355 49467140 Copy number Hodgkin''s lymphoma
17 44594 10 60095355 78914295 Copy number Hodgkin''s lymphoma
18 44784 10 6277674 8346525 Copy number Hodgkin''s lymphoma
19 45116 10 67551761 78914295 Copy number Hodgkin''s lymphoma
20 46267 10 79687952 85721525 Copy number Hodgkin''s lymphoma
21 46788 10 86278375 101096913 Copy number Hodgkin''s lymphoma
22 49260 11 104569097 133732868 Copy number Hodgkin''s lymphoma
23 50177 11 115327798 134437143 Copy number Hodgkin''s lymphoma
24 52493 11 178227 35140556 Copy number Hodgkin''s lymphoma
25 57515 11 63560139 72573784 Copy number Hodgkin''s lymphoma
26 57783 11 64800000 75000000 Gain Hodgkin''s lymphoma
27 58506 11 68129639 134437143 Copy number Hodgkin''s lymphoma
28 60254 11 84447402 105734987 Copy number Hodgkin''s lymphoma
29 60677 11 89286313 104569095 Copy number Hodgkin''s lymphoma
30 64335 12 126737931 132373208 Copy number Hodgkin''s lymphoma
31 65226 12 152534 16164790 Copy number Hodgkin''s lymphoma
32 65227 12 152534 525774777 Copy number Hodgkin''s lymphoma
33 67817 12 4490384 44739500 Copy number Hodgkin''s lymphoma
34 67821 12 45000000 56400000 Gain Hodgkin''s lymphoma
35 68783 12 51500000 63100000 Gain Hodgkin''s lymphoma
36 68979 12 52417126 60370345 Copy number Hodgkin''s lymphoma
37 69531 12 55627899 56288135 Copy number Hodgkin''s lymphoma
38 70095 12 58245748 132373208 Copy number Hodgkin''s lymphoma
39 70715 12 64263728 66931770 Copy number Hodgkin''s lymphoma
40 71442 12 70000000 82000000 Gain Hodgkin''s lymphoma
41 72563 12 82669309 120958351 Copy number Hodgkin''s lymphoma
42 75245 13 18397782 106691271 Copy number Hodgkin''s lymphoma
43 75246 13 18397782 114117460 Copy number Hodgkin''s lymphoma
44 75871 13 25400000 38500000 Loss Hodgkin''s lymphoma
45 75878 13 25500000 32200000 Loss Hodgkin''s lymphoma
46 79388 13 71000000 83000000 Loss Hodgkin''s lymphoma
47 83222 14 19570807 42171562 Copy number Hodgkin''s lymphoma
48 83386 14 20383489 53262838 Copy number Hodgkin''s lymphoma
49 83387 14 20383489 56623380 Copy number Hodgkin''s lymphoma
50 85558 14 48879628 106278173 Copy number Hodgkin''s lymphoma

Expression for Hodgkin Lymphoma

Search GEO for disease gene expression data for Hodgkin Lymphoma.

Pathways for Hodgkin Lymphoma

Pathways related to Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show all 23)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 ALK BCL2 BRAF CASP10 CSF3 FAS
2
Show member pathways
13.53 ALK BCL2 BRAF CASP10 CSF3 FAS
3
Show member pathways
13.26 ALK BCL2 CSF3 FAS IL6 LTA
4
Show member pathways
13.17 BCL2 BCL6 BRAF CSF3 FSCN1 IL6
5
Show member pathways
12.97 BCL2 CASP10 CSF3 FAS IL6 LTA
6
Show member pathways
12.76 BCL2 CASP10 FAS IL6 REL
7
Show member pathways
12.48 BCL2 CASP10 FAS LTA TNFRSF8 TNFSF8
8 12.43 BCL6 FAS PAX5 PRDM1 REL
9 12.12 BCL6 IL6 PAX5 REL
10 11.88 BCL2 BCL6 FSCN1 IL6
11 11.84 CASP10 FAS IL6 LTA
12 11.81 BCL2 BRAF IL6
13
Show member pathways
11.81 BCL6 CASP10 FAS
14 11.76 CSF3 IL6 MS4A1
15
Show member pathways
11.74 CSF3 IL6 REL
16 11.67 BCL2 BCL6 CASP10 FAS PRDM1
17
Show member pathways
11.66 FAS LTA TNFRSF8 TNFSF8
18 11.63 IL6 LY75 MS4A1
19
Show member pathways
11.49 BCL2 REL TNFRSF8 TNFSF8
20 11.44 BCL2 FAS IL6
21 11.2 BCL6 IL6 LTA PAX5 PRDM1
22 11 BCL2 CSF3 IL6 LTA TNFSF8
23 10.75 BCL6 MS4A1 PAX5 PRDM1 TNFRSF8

GO Terms for Hodgkin Lymphoma

Cellular components related to Hodgkin Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 CD95 death-inducing signaling complex GO:0031265 8.62 CASP10 FAS

Biological processes related to Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.92 BCL2 BCL6 IL6 NPM1 TNFRSF8
2 negative regulation of apoptotic process GO:0043066 9.88 BCL2 BCL6 BRAF FAS IL6 NPM1
3 positive regulation of apoptotic process GO:0043065 9.85 BCL6 FAS IL6 LTA TNFRSF8
4 inflammatory response GO:0006954 9.85 BCL6 FAS IL6 LY75 REL TNFRSF8
5 response to lipopolysaccharide GO:0032496 9.81 FAS IL6 LTA TNFRSF8
6 immune response GO:0006955 9.8 CSF3 FAS IL6 LTA LY75 TNFRSF8
7 apoptotic signaling pathway GO:0097190 9.74 CASP10 FAS TNFRSF8
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.73 FAS LTA TNFRSF8 TNFSF8
9 response to glucocorticoid GO:0051384 9.72 BCL2 FAS IL6
10 defense response to Gram-positive bacterium GO:0050830 9.71 IL6 LTA TNFSF8
11 response to cytokine GO:0034097 9.67 BCL2 IL6 REL
12 negative regulation of neuron death GO:1901215 9.65 CSF3 IL6 REL
13 regulation of apoptotic process GO:0042981 9.63 ALK BCL2 BCL6 CASP10 FAS IL6
14 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.62 BCL2 BRAF CSF3 IL6
15 renal system process GO:0003014 9.56 BCL2 FAS
16 regulation of cell proliferation GO:0042127 9.43 ALK BCL6 BRAF FAS IL6 PRDM1
17 humoral immune response GO:0006959 9.02 BCL2 IL6 LTA MS4A1 PAX5

Molecular functions related to Hodgkin Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 CSF3 IL6 LTA TNFSF8

Sources for Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....